These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9249225)

  • 41. The angiotensin II receptor antagonist losartan: a new advance in the treatment of hypertension.
    Lacourcière Y
    Can J Cardiol; 1995 Aug; 11 Suppl F():45F-48F. PubMed ID: 7664218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Angiotensin receptor antagonists. A new class of antihypertensive agents].
    Mann J
    Dtsch Med Wochenschr; 1996 Apr; 121(17):568-71. PubMed ID: 8620827
    [No Abstract]   [Full Text] [Related]  

  • 43. Failure of losartan to control blood pressure in scleroderma renal crisis.
    Caskey FJ; Thacker EJ; Johnston PA; Barnes JN
    Lancet; 1997 Mar; 349(9052):620. PubMed ID: 9057740
    [No Abstract]   [Full Text] [Related]  

  • 44. Angiotensin II receptor antagonism: losartan - sites and mechanisms of action.
    Triggle DJ
    Clin Ther; 1995; 17(6):1005-30. PubMed ID: 8750395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Antagonists of angiotensin II receptor].
    Karasek D; Adamski M; Grzeszczak W
    Postepy Hig Med Dosw; 1996; 50(1):21-32. PubMed ID: 8778711
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The first clinical experience in Italy with angiotensin II receptor antagonists: results of a multicenter study on the efficacy and tolerance in arterial hypertension].
    Trimarco B
    Cardiologia; 1995 Dec; 40(12 Suppl 1):193-5. PubMed ID: 8998714
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical experience with angiotensin II receptor antagonists.
    Brunner HR; Christen Y; Munafo A; Lee RJ; Waeber B; Nussberger J
    Am J Hypertens; 1992 Dec; 5(12 Pt 2):243S-246S. PubMed ID: 1290619
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.
    Crozier I; Ikram H; Awan N; Cleland J; Stephen N; Dickstein K; Frey M; Young J; Klinger G; Makris L
    Circulation; 1995 Feb; 91(3):691-7. PubMed ID: 7828295
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-hypertensive therapy by losartan. How effective is AT1 receptor blockade?
    Brunner HR
    J Hum Hypertens; 1995 Nov; 9(11):859-60. PubMed ID: 8583462
    [No Abstract]   [Full Text] [Related]  

  • 50. Losartan in post-transplant erythrocytosis.
    Conlon PJ; Smith SR; Butterly DW; Brennan DC
    Nephrol Dial Transplant; 1996 Dec; 11(12):2524-5. PubMed ID: 9017645
    [No Abstract]   [Full Text] [Related]  

  • 51. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure].
    Rakugi H; Ogihara T
    Nihon Rinsho; 2001 Oct; 59(10):2051-61. PubMed ID: 11676153
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension.
    Ruff D; Gazdick LP; Berman R; Goldberg AI; Sweet CS
    J Hypertens; 1996 Feb; 14(2):263-70. PubMed ID: 8728306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Angiotensin II receptor blockers. A new class of antihypertensive drugs.
    Velasquez MT
    Arch Fam Med; 1996 Jun; 5(6):351-6. PubMed ID: 8640326
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.
    Tsunoda K; Abe K; Hagino T; Omata K; Misawa S; Imai Y; Yoshinaga K
    Am J Hypertens; 1993 Jan; 6(1):28-32. PubMed ID: 8427658
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rationale for the chemical development of angiotensin II receptor antagonists.
    Wexler RR; Carini DJ; Duncia JV; Johnson AL; Wells GJ; Chiu AT; Wong PC; Timmermans PB
    Am J Hypertens; 1992 Dec; 5(12 Pt 2):209S-220S. PubMed ID: 1290616
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A risk-benefit assessment of losartan potassium in the treatment of hypertension.
    Burrell LM
    Drug Saf; 1997 Jan; 16(1):56-65. PubMed ID: 9010643
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan.
    Bunt T
    Clin Ther; 1999 Mar; 21(3):611-2. PubMed ID: 10321426
    [No Abstract]   [Full Text] [Related]  

  • 58. [Fast-acting sartan. High blood pressure therapy without long waiting time].
    MMW Fortschr Med; 2003 Jun; 145(24):55. PubMed ID: 12866306
    [No Abstract]   [Full Text] [Related]  

  • 59. Benefit of angiotensin II receptor blockade in the treatment of posttransplant polycythemia in renal transplant recipients.
    Kupin W; Venkat KK; Goggins M; Abouljoud M; Escobar F; Mozes M
    Transplant Proc; 1997; 29(1-2):207-8. PubMed ID: 9122965
    [No Abstract]   [Full Text] [Related]  

  • 60. Antiproteinuric effect of Losartan in patients with chronic renal diseases.
    Zoccali C; Valvo E; Russo D; Panichi V; Zuccala' A
    Nephrol Dial Transplant; 1997 Jan; 12(1):234-5. PubMed ID: 9027813
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.